144 related articles for article (PubMed ID: 12452445)
1. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer.
Kumpulainen EJ; Keskikuru RJ; Johansson RT
Breast Cancer Res Treat; 2002 Nov; 76(2):95-102. PubMed ID: 12452445
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
4. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer.
McLaughlin R; McGrath J; Grimes H; Given HF
Int J Biol Markers; 2000; 15(4):340-2. PubMed ID: 11192831
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
[TBL] [Abstract][Full Text] [Related]
7. CA 15-3: a prognostic marker in breast cancer.
Duffy MJ; Shering S; Sherry F; McDermott E; O'Higgins N
Int J Biol Markers; 2000; 15(4):330-3. PubMed ID: 11192829
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
[TBL] [Abstract][Full Text] [Related]
9. Serum markers and prognosis in locally advanced breast cancer.
Martínez-Trufero J; de Lobera AR; Lao J; Puértolas T; Artal-Cortés A; Zorrilla M; Alonso V; Pazo R; Valero MI; Ríos-Mitchell MJ; Calderero V; Herrero A; Antón A
Tumori; 2005; 91(6):522-30. PubMed ID: 16457152
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
11. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer?
Velaiutham S; Taib NA; Ng KL; Yoong BK; Yip CH
Asian Pac J Cancer Prev; 2008; 9(3):445-8. PubMed ID: 18990019
[TBL] [Abstract][Full Text] [Related]
12. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study.
Bhatavdekar JM; Patel DD; Karelia NH; Vora HH; Ghosh N; Shah NG; Balar DB; Trivedi SN
Breast Cancer Res Treat; 1994; 30(3):293-7. PubMed ID: 7981447
[TBL] [Abstract][Full Text] [Related]
15. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
[TBL] [Abstract][Full Text] [Related]
16. Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.
El-Abd E; El-Sheikh M; Zaky S; Fayed W; El-Zoghby S
Cancer Biomark; 2017 Aug; 20(2):123-133. PubMed ID: 28869444
[TBL] [Abstract][Full Text] [Related]
17. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CA 15.3 kinetics for metastatic breast cancer.
De La Lande B; Hacene K; Floiras JL; Alatrakchi N; Pichon MF
Int J Biol Markers; 2002; 17(4):231-8. PubMed ID: 12521126
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease.
Berruti A; Tampellini M; Torta M; Buniva T; Gorzegno G; Dogliotti L
Eur J Cancer; 1994; 30A(14):2082-4. PubMed ID: 7857707
[TBL] [Abstract][Full Text] [Related]
20. CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):63-6. PubMed ID: 23260003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
